Trialists’ Insights on the 2-year results from the COMPARE Trial

Discussion between Dr Michael Jaff and Dr Sabine Steiner on COMPARE trial, World’s first head-to-head, Prospective, Multi-Center RCT (1:1) comparing the lower dose Paclitaxel RANGER™ DCB to the higher dose Paclitaxel IN.PACT™ DCB


Ranger image

Ranger™ Paclitaxel-Coated PTA Balloon Catheter

Supported by robust clinical evidence, Ranger provides exceptional outcomes, effortless deliverability, and efficient drug transfer.


Eluvia™ Drug-Eluting Vascular Stent System

Eluvia provides consistent, durable outcomes in challenging SFA disease and features a polymer design for controlled drug release.


Strengthen Quality Outcomes

Boston Scientific is the only company providing Level-1 Head-to-Head Randomized Controlled Clinical Trials in the PAD space for DES and DCB, helping physicians make more informed treatment decisions.


Enhance Patient Experience

Ranger DCB and Eluvia DES were purposely designed to deliver the lowest possible drug dose through efficient drug transfer to achieve high patency with low systemic drug exposure to the patient.


Increase Operational Efficiencies

Ranger DCB is .014” guidewire compatible to help streamline atherectomy procedures. Eluvia DES has shown to reduce hospital length of stay and readmission rates.


Improve Financial Health

Boston Scientific is the only company offering both DES and DCB, with the largest PI portfolio to streamline hospital supply chain management.


Eluvia and Ranger are registered or unregistered trademarks of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners.


Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

1. Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.

2. Versus 87.0% primary patency in the none/mild calcium arm of the IMPERIAL Calcium Subgroup.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Information not intended for use or distribution in France.
All trademarks are property of their respective owners.